Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Brigatinib Solution vs Tablet in Healthy Adults
NCT06132867Phase 1Completed
- Sponsor
- Takeda
- Start
- Dec 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at 168 hours, Area Under the Plasma Concentration-Time Curve to Last Quantifiable Concentration at 168 hours and 1 more. Started Dec 2023; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06132867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132867.